Article

News Briefs

Diane G. Cope

nurse education
CJON 2002, 6(3), 124-125. DOI: 10.1188/02.CJON.124-125

On February 1, the U.S. Food and Drug Administration (FDA) approved Gleevec™ (imantinib mesylate, Novartis Pharmaceuticals, Basel, Switzerland) for the treatment of patients with metastatic or unresectable malignant gastrointestinal stromal tumors (GIST).

Members Only
Not a current ONS member or journal subscriber?

Become a Member

Explore the benefits of membership.
Join ONS or Renew Membership

Purchase This Article

Receive a PDF to download and print.